Tvardi Therapeutics, Inc. (TVRD) - Net Assets
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has net assets worth $27.87 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($39.02 Million) and total liabilities ($11.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tvardi Therapeutics, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.87 Million |
| % of Total Assets | 71.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 55.59 |
Tvardi Therapeutics, Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Tvardi Therapeutics, Inc. asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual net assets of Tvardi Therapeutics, Inc. from 2020 to 2024. For live valuation and market cap data, see TVRD market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-4.59 Million | +92.60% |
| 2023-12-31 | $-62.06 Million | -37.75% |
| 2022-12-31 | $-45.05 Million | -119.80% |
| 2021-12-31 | $227.52 Million | -8.63% |
| 2020-12-31 | $249.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tvardi Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36329500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | % |
| Other Components | $751.01 Million | % |
| Total Equity | $-4.59 Million | 100.00% |
Tvardi Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
$29.44 Million |
|
HICL Infrastructure Company Ltd
LSE:HICL
|
$29.44 Million |
|
Bintai Kinden Corporation Bhd
KLSE:6998
|
$29.45 Million |
|
Elon AB (publ)
ST:ELON
|
$29.46 Million |
|
Norse Atlantic ASA
OL:NORSE
|
$29.39 Million |
|
Shaftesbury Capital PLC
LSE:SHC
|
$29.39 Million |
|
International Public Partnership
LSE:INPP
|
$29.38 Million |
|
Churchill Resources Inc
V:CRI
|
$29.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tvardi Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -62,058,000 to -4,593,000, a change of 57,465,000.
- Net loss of 70,867,000 reduced equity.
- Other comprehensive income increased equity by 260,000.
- Other factors increased equity by 128,072,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.87 Million | -1542.93% |
| Other Comprehensive Income | $260.00K | +5.66% |
| Other Changes | $128.07 Million | +2788.42% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Tvardi Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $187.08 | $3.14 | x |
| 2021-12-31 | $161.49 | $3.14 | x |
| 2022-12-31 | $-4.82 | $3.14 | x |
| 2023-12-31 | $-6.63 | $3.14 | x |
| 2024-12-31 | $-3.02 | $3.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tvardi Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -992.95%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-7.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 3.38% | 6.23% | 0.50x | 1.09x | $-16.49 Million |
| 2021 | -38.87% | -384.06% | 0.09x | 1.09x | $-111.19 Million |
| 2022 | 0.00% | -204.16% | 0.93x | 0.00x | $-80.97 Million |
| 2023 | 0.00% | -565.21% | 0.78x | 0.00x | $-112.31 Million |
| 2024 | 0.00% | -992.95% | 0.16x | 0.00x | $-70.41 Million |
Industry Comparison
This section compares Tvardi Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $27.87 Million | 3.38% | 0.40x | $29.39 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more